About

Dr. Sehgal completed his PhD in 2019 from Chinese Academy of Sciences. Dr. Sehgal intends to design active biomolecules by utilizing in silico analyses and also develop novel approaches to scrutinize the novel compounds against auto(mito)phagy, cancer and neurodegenerative disorders. He works on immunoinformatics analyses to reveal potential epitope-based peptide vaccines. He has expertise in computational phylogenetics analyses and evolutionary biology. He has expertise to verify the computationally scrutinized compounds in wet lab experiments.

He has authored/co-authored thirty (30) research/review articles (having ~152 IF) in peer reviewed journals and two (02) complete book as principle and corresponding author. For his contributions in the field, he was awarded with Research Productivity Award for the year of 2015, 2016 and 2017 by CUI, and CAS-TWAS president fellowship award 2015. Moreover, in 2018, he was honored with the Excellent International Student of UCAS 2018.

Research Interests

Computational Drug Design, Auto(mito)phagy, Proteomics, Computational Evolutionary Biology

Awards and Honors

For his contributions in the field, he was awarded with Research Productivity Award for the year of 2015, 2016 and 2017 by CUI, and CAS-TWAS president fellowship award 2015. Moreover, in 2018, he was honored with the Excellent International Student of UCAS 2018.

Publications

Corresponding Author

• Epidemiological studies of sleep disorder in educational community of Pakistani population, its major risk factors and associated diseases.PloS one2022, 17 (4), e0266739 (IF: 3.14)
• Epitope-based peptide vaccine design and elucidation of novel compounds against 3C like protein of SARS-CoV-2. Plos one 2022, 17.3 e0264700 (IF: 3.14)
• Immunoinformatics and Molecular Docking Studies Predicted Potential Multiepitope-Based Peptide Vaccine and Novel Compounds against Novel SARS-CoV-2 through Virtual Screening. BioMed Research International, 2021, (IF: 3.411)
•  The life cycle and in silico elucidation of non-structural replicating proteins of HCV through a pharmacoinformatics approach. Combinatorial Chemistry & High Throughput Screening, 2021 (IF: 1.339)
• Anti-aging natural compounds and their role in the regulation of metabolic pathways leading to longevity. Mini Reviews in Medicinal Chemistry, 2021, (IF: 3.860)
• Determine the potential Epitope based Peptide Vaccine against novel SARS-CoV-2 targeting structural proteins using immunoinformatics approaches. Frontiers in Molecular Biosciences, 2020, 7, 227 (IF: 5.246)
• In Silico identification of angiotensin-converting enzyme inhibitory peptides from MRJP1. PloS One, 2020, 15 (2), e0228265. (IF: 3.240)
• Ligand-Based Pharmacophore Modeling and Virtual Screening to Discover Novel CYP1A1 Inhibitors. Current Topics in Medicinal Chemistry, 2019, 19 (30), 2782-2794. (IF: 3. 3.295)
• Pharmacoinformatics and molecular docking reveal potential drug candidates against Schizophrenia to target TAAR6. Journal of Cellular Physiology, 2019, 234 (8), 13263-13276. (IF: 6.384)
• Immunoinformatics and molecular docking studies reveal potential Epitope based Peptide Vaccine against DENV-NS3 Protein. Journal of Theoretical Biology, 2018, 459, 162-170. (IF: 2.691)
• Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design. Current Neuropharmacology, 2018, 16(6), 649-663. (IF: 7.360)
• Pharmacoinformatics and Molecular Docking Studies Reveal Potential Novel Compounds Against Schizophrenia by Target SYN II. Combinatorial Chemistry & High Throughput Screening 2018, 21(3), 175-181. (IF: 1.339)
• Pharmacoinformatics and molecular docking studies reveal potential novel Proline Dehydrogenase (PRODH) compounds for Schizophrenia inhibition. Medicinal Chemistry Research 2017, 26(2), 314-326. (IF: 1.965)
• Pharmacoinformatics, Adaptive Evolution, and Elucidation of Six Novel Compounds for Schizophrenia Treatment by Targeting DAOA (G72) Isoforms. BioMed Research International, 2017,Article ID 5925714, doi:10.1155/2017/5925714. (IF: 3.411)
• Pharmacoinformatic and molecular docking studies reveal potential novel antidepressants against neurodegenerative disorders by targeting HSPB. Drug Design Development and Therapy 2016, 10, 1605 (IF: 4.162)
• Comparative Modeling, Molecular Docking, and Revealing of Potential Binding Pockets of RASSF2; a Candidate Cancer Gene. Interdisciplinary Sciences: Computational Life Sciences, 2017, 9(2), 214-223. (IF: 2.233)

Principal Author

• Molecular docking analyses of CYP450 monooxygenases of Tribolium castaneum (Herbst) reveal synergism of quercetin with paraoxon and tetraethyl pyrophosphate: in vivo and in silico studies. Toxicology Research, 2020, tfaa023, https://doi.org/10.1093/toxres/tfaa023. (IF: 3.524)
• Adaptive Evolution and Elucidating the potential inhibitor against Schizophrenia to target DAOA (G72) Isoforms. Drug Design Development and Therapy 2015, 9, 3471 (IF: 4.162)
• Pharmacoinformatics elucidation of potential drug targets against migraine to target ion channel protein KCNK18. Drug Design Development and Therapy 2014 8, 571-581. (IF: 4.162)
• Tumor Necrosis Factor Receptor Superfamily 10B (TNFRSF10B), An insight from structure modeling to virtual screening for designing drug against head and neck cancer. Theoretical Biology and Medical Modeling 2013, 10:38. (IF: 2.432)
• Structural, phylogenetic and docking studies of D-amino acid oxidase activator (DAOA), a candidate schizophrenia gene. Theoretical Biology and Medical Modeling 2013, 10:1. (IF: 2.432)

Co-Author

• The multifaceted regulation of mitophagy by endogenous metabolites. Autophagy, 2021, doi.org/10.1080/15548627.2021.1975914. (IF: 16.016)
• Defective mitochondrial ISCs biogenesis switches on IRP1 to fine tune selective mitophagy. Redox Biology, 2020, 101661 (IF: 11.799)
• Identification of effective membrane efflux transporters against β‐amyrin through molecular docking approach. Journal of Chemical Technology & Biotechnology, 2019 94 (9), 2869-2875. (IF: 3.174)
• STING directly activates autophagy to tune the innate immune response. Cell Death and Differentiation 2019, 26 (9), 1735-1749 (IF: 15.828)
• Prevalence of Extended Spectrum β-Lactamases in Multi-drug Resistant Pseudomonas aeruginosa from Diabetic Foot Patients. Endocrine, Metabolic & Immune Disorders Drug Targets 2019, 19(4), 443-448 doi.org/10.2174/1871530319666181128095753. (IF: 2.895)
• Formulation and Characterization of a Self-Emulsifying Drug Delivery System (SEDDS) of Curcumin for the Topical Application in Cutaneous and Mucocutaneous Leishmaniasis. Current Topics in Medicinal Chemistry 2018, 18(18), 1603-1609. (IF: 3.295)
• In Silico characterization and In-Vivo validation of Albiziasaponin-A, Iso-Orientin and Salvadorin using a rat model of Alzheimer’s disease. Frontiers in Pharmacology 2018, 9, 730. (IF: 5.810)
• Comparative in silico analyses of Cannabis sativa, Prunella vulgaris and Withania somnifera compounds elucidating the medicinal properties against rheumatoid arthritis. Journal of Molecular Graphics and Modelling 2017, 74, 296-304 (IF: 2.518)
• Mitochondrial E3 ligase MARCH5 regulates FUNDC1 to fine‐tune hypoxic mitophagy. EMBO reports, 2017, 18(3), 495-509 p.e201643309. (IF: 8.807)
• Mitophagy Receptors Sense Stress Signals and Couple Mitochondrial Dynamic Machinery for Mitochondrial Quality Control. Free Radical Biology and Medicine 2016 100, 199-209. (IF: 7.376)
• Regulatory cascade of neurological loss and glucose metabolism. CNS & Neurological Disorders - Drug Targets 2014 13(7), 1232-1245. (IF: 4.388)

Books             

• Quick Guideline for Computational Drug Design. 2018 Bentham Science Publishers (First and Corresponding author) (ISBN: 978-1-68108-604-0)
• Quick Guideline for Computational Drug Design Revised Edition 2021 Bentham Science Publishers (First and Corresponding author) (ISBN: 978-981-4998-70-3)

Affiliations

Department of Bioinformatics, The Islamia University of Bahawalpur, 63100-Pakistan